Scholarlink

<p>Bladder cancer is a common and lethal malignancy with high treatment costs due to frequent recurrence and prolonged therapy. Despite therapeutic advances, many patients develop drug-resistant metastatic disease, underscoring the need for new treatments. Using the STROBE-MR guidelines, we performed Mendelian randomization with cis- expression quantitative trait loci (eQTLs) from the eQTLGen Consortium (n = 31,684) as exposures. Two independent cohorts served as discovery and replication sets for target identification. Drug prediction and molecular docking were applied to validate the targets. Twelve significant drug targets were identified. Phenome-wide association study revealed additional associations of NDST1 and HMGCR with proteomic traits and health service use, respectively. Molecular docking confirmed strong binding for available protein structures. Our study identified 12 promising drug targets for bladder cancer and suggests that MR-based prioritization may improve clinical trial success and reduce development costs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Identification of potential bladder cancer drug targets through Mendelian randomization and molecular docking

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月26日

查看全文
  • Chengwei Bi,
  • Kexun Li,
  • Yong Yang,
  • Yuanlong Shi,
  • Guoying Zhang,
  • Bing Zhao,
  • Yuanpeng Duan,
  • Yapeng Xing,
  • Wei Luo,
  • Libo Yang,
  • Yu Zhang,
  • Yunchao Huang

摘要

Bladder cancer is a common and lethal malignancy with high treatment costs due to frequent recurrence and prolonged therapy. Despite therapeutic advances, many patients develop drug-resistant metastatic disease, underscoring the need for new treatments. Using the STROBE-MR guidelines, we performed Mendelian randomization with cis- expression quantitative trait loci (eQTLs) from the eQTLGen Consortium (n = 31,684) as exposures. Two independent cohorts served as discovery and replication sets for target identification. Drug prediction and molecular docking were applied to validate the targets. Twelve significant drug targets were identified. Phenome-wide association study revealed additional associations of NDST1 and HMGCR with proteomic traits and health service use, respectively. Molecular docking confirmed strong binding for available protein structures. Our study identified 12 promising drug targets for bladder cancer and suggests that MR-based prioritization may improve clinical trial success and reduce development costs.